-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, benefiting from the reform of the IPO system and the encouragement of related pharmaceutical policies, many innovative pharmaceutical companies have flocked to the capital market
.
According to the analysis, as of December 15th, 34 biopharmaceutical companies have been listed on the Science and Technology Innovation Board during the year, and two companies, Nanmo Biology and Chunli Medical, have obtained listing permits from the China Securities Regulatory Commission
.
Among them, it is worth mentioning that just over half of December, at least 6 pharmaceutical companies have been successfully listed
.
On December 15, BeiGene was listed on the Science and Technology Innovation Board and became the world's first biopharmaceutical company listed on the US, Hong Kong and A shares
.
On the first day of listing on the Science and Technology Innovation Board, BeiGene opened at 176.
96 yuan
.
BeiGene's issue price is 192.
6 yuan per share, and the total amount of funds raised is expected to reach 22.
16 billion yuan
.
On December 10, Dizhe Pharmaceutical was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange
.
It is understood that this time on the Sci-tech Innovation Board, Dizhe Pharmaceutical issued 40,001 million shares of the company.
The number of publicly issued shares is 10% of the total share capital after the issuance; this issuance does not involve the original shareholders’ public offering of shares.
The total share capital is approximately 400 million shares
.
The total amount of funds raised is 2.
1 billion yuan
.
It is worth mentioning that after the listing of the new stock, the new market value once exceeded 10 billion yuan, reaching 16.
4 billion yuan
.
On December 10, Kailaiying was listed on the main board of the Hong Kong Stock Exchange and listed for trading
.
This is the second listing of Calais.
Calais Pharmaceuticals, which landed on the A-share market five years ago, is now a domestic chemical drug commercial outsourcing production (CDMO) giant with a market value of over 100 billion yuan
.
The net fundraising of Gloria Ying is approximately HK$6.
85 billion
.
Among them, 20% is used to increase the production capacity and capabilities of small molecule CDMOs, 35% to strengthen emerging services, 20% to invest in R&D projects and upgrade technology platforms, 15% to strategic investments and acquisitions, and 10% to company operating funds
.
On December 10, Beihai Kangcheng officially listed on the Hong Kong Stock Exchange
.
Founded in 2012, the company is a biomedical company based in China, focusing on rare diseases, dedicated to research, development and commercialization of biotech therapies
.
Beihai Kangcheng intends to issue 56.
251 million shares for this listing, and another 15% over-allotment equity
.
Morgan Stanley and Jefferies are joint sponsors
.
For this IPO, Beihai Kangcheng and six cornerstone investors (including RA Capital, Hudson Bay, Janus Capital, WuXi Biologics, etc.
) have entered into a cornerstone investment agreement and agreed to subscribe for a total of approximately US$60 million in shares at the offer price
.
On December 10, Gushengtang Holdings Co.
, Ltd.
was successfully listed on the main board of the Hong Kong Stock Exchange
.
Public information shows that the listing price of Gushengtang is 29 Hong Kong dollars per share, and the net fundraising amount is about 700 million Hong Kong dollars
.
69.
8% of the proceeds will be used to expand online and offline businesses and strengthen the integration of online and offline businesses; 9.
6% will be used to strengthen R&D capabilities; 9.
6% will be used to strengthen supply chain capabilities; 4.
9% will be used for marketing and brand promotion activities; 6% will be used For working capital and general corporate purposes
.
On December 7, Hunan Dajia Weikang Pharmaceutical Industry Co.
, Ltd.
(hereinafter referred to as "Dajia Weikang") was officially listed on the ChiNext of the Shenzhen Stock Exchange
.
The company’s issuance is priced at 12.
37 yuan and the issuance price-earnings ratio is 40.
58 times.
A total of 51,626,425 new shares were issued.
The total amount of funds raised reached 639 million yuan, which was 129 million yuan higher than the planned funds raised.
The funds raised will be mainly used for the company's smart logistics center.
Construction, expansion of chain pharmacies and repayment of bank loans
.
.
According to the analysis, as of December 15th, 34 biopharmaceutical companies have been listed on the Science and Technology Innovation Board during the year, and two companies, Nanmo Biology and Chunli Medical, have obtained listing permits from the China Securities Regulatory Commission
.
Among them, it is worth mentioning that just over half of December, at least 6 pharmaceutical companies have been successfully listed
.
On December 15, BeiGene was listed on the Science and Technology Innovation Board and became the world's first biopharmaceutical company listed on the US, Hong Kong and A shares
.
On the first day of listing on the Science and Technology Innovation Board, BeiGene opened at 176.
96 yuan
.
BeiGene's issue price is 192.
6 yuan per share, and the total amount of funds raised is expected to reach 22.
16 billion yuan
.
On December 10, Dizhe Pharmaceutical was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange
.
It is understood that this time on the Sci-tech Innovation Board, Dizhe Pharmaceutical issued 40,001 million shares of the company.
The number of publicly issued shares is 10% of the total share capital after the issuance; this issuance does not involve the original shareholders’ public offering of shares.
The total share capital is approximately 400 million shares
.
The total amount of funds raised is 2.
1 billion yuan
.
It is worth mentioning that after the listing of the new stock, the new market value once exceeded 10 billion yuan, reaching 16.
4 billion yuan
.
On December 10, Kailaiying was listed on the main board of the Hong Kong Stock Exchange and listed for trading
.
This is the second listing of Calais.
Calais Pharmaceuticals, which landed on the A-share market five years ago, is now a domestic chemical drug commercial outsourcing production (CDMO) giant with a market value of over 100 billion yuan
.
The net fundraising of Gloria Ying is approximately HK$6.
85 billion
.
Among them, 20% is used to increase the production capacity and capabilities of small molecule CDMOs, 35% to strengthen emerging services, 20% to invest in R&D projects and upgrade technology platforms, 15% to strategic investments and acquisitions, and 10% to company operating funds
.
On December 10, Beihai Kangcheng officially listed on the Hong Kong Stock Exchange
.
Founded in 2012, the company is a biomedical company based in China, focusing on rare diseases, dedicated to research, development and commercialization of biotech therapies
.
Beihai Kangcheng intends to issue 56.
251 million shares for this listing, and another 15% over-allotment equity
.
Morgan Stanley and Jefferies are joint sponsors
.
For this IPO, Beihai Kangcheng and six cornerstone investors (including RA Capital, Hudson Bay, Janus Capital, WuXi Biologics, etc.
) have entered into a cornerstone investment agreement and agreed to subscribe for a total of approximately US$60 million in shares at the offer price
.
On December 10, Gushengtang Holdings Co.
, Ltd.
was successfully listed on the main board of the Hong Kong Stock Exchange
.
Public information shows that the listing price of Gushengtang is 29 Hong Kong dollars per share, and the net fundraising amount is about 700 million Hong Kong dollars
.
69.
8% of the proceeds will be used to expand online and offline businesses and strengthen the integration of online and offline businesses; 9.
6% will be used to strengthen R&D capabilities; 9.
6% will be used to strengthen supply chain capabilities; 4.
9% will be used for marketing and brand promotion activities; 6% will be used For working capital and general corporate purposes
.
On December 7, Hunan Dajia Weikang Pharmaceutical Industry Co.
, Ltd.
(hereinafter referred to as "Dajia Weikang") was officially listed on the ChiNext of the Shenzhen Stock Exchange
.
The company’s issuance is priced at 12.
37 yuan and the issuance price-earnings ratio is 40.
58 times.
A total of 51,626,425 new shares were issued.
The total amount of funds raised reached 639 million yuan, which was 129 million yuan higher than the planned funds raised.
The funds raised will be mainly used for the company's smart logistics center.
Construction, expansion of chain pharmacies and repayment of bank loans
.
